Galecto (NASDAQ: GLTO), a clinical stage biotechnology company focused on the development of novel treatments for fibrosis and cancer, has announced positive results from intermediate assessment of its ongoing Phase 2a trial of GB2064 for the treatment of myelofibrosis.

Intermediate assessments have shown that four out of five evaluable myelofibrosis patients who received the GB2064 monotherapy for at least six months experienced a greater than or equal to 1-grade reduction in collagen fibrosis of the bone marrow. This improvement suggest that the company’s GB2064 could impact the progression of the disease and be disease modifying.

Dr. Hans Schambye, President and CEO of Galecto, commented: “We are very excited to have demonstrated proof of principle with GB2064 showing an anti-fibrotic effect in a difficult-to-treat patient population. These intermediate results strengthen our belief that GB2064 has the potential to be a disease-modifying therapy for multiple cancers and fibrotic diseases.”

The MYLOX-1 clinical trial is an ongoing Phase 2, open-label, single-arm study in myelofibrosis patients who are ineligible, refractory or intolerant to JAK inhibitor therapy. These patients have a progressive disease with poor quality of life, high mortality rates, and very limited treatment options. The primary endpoint of the ongoing MYLOX-1 trial is an assessment of safety and tolerability, while secondary endpoints focus on measurements of bone marrow fibrosis and hematological parameters

Galecto is a clinical stage company incorporated in the U.S. that is developing small molecule-based inhibitors of galectin-3 and LOXL2. Galecto has four ongoing Phase 2 clinical programs in fibrosis and cancer.

Shares of Galecto trade on the NASDAQ under the ticker symbol GLTO.